-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
DMK PHARMACEUTICALS Corp quarterly/annual Earnings Per Share, Diluted history and growth rate from Q1 2014 to Q3 2023.
- DMK PHARMACEUTICALS Corp Earnings Per Share, Diluted for the quarter ending September 30, 2023 was -0.2 USD/shares, a 90.2% increase year-over-year.
- DMK PHARMACEUTICALS Corp Earnings Per Share, Diluted for the twelve months ending September 30, 2023 was 2.2 USD/shares.
- DMK PHARMACEUTICALS Corp annual Earnings Per Share, Diluted for 2022 was -0.18 USD/shares, a 43.8% increase from 2021.
- DMK PHARMACEUTICALS Corp annual Earnings Per Share, Diluted for 2021 was -0.32 USD/shares.
- DMK PHARMACEUTICALS Corp annual Earnings Per Share, Diluted for 2016 was -1.19 USD/shares, a 15.5% decline from 2015.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Growth (%)